Skip to main content

Table 1 Clinical characteristics and sputum sample inflammatory characteristics of all participants at baseline

From: Effects of treatment changes on asthma phenotype prevalence and airway neutrophil function

 

Neutrophilic asthma

(NA)

Paucigranulocytic asthma

(PGA)

Eosinophilic asthma

(EA)

All asthma

No asthma

Number (% of asthma)

4 (8%)

26 (52%)

20 (40%)

50

39

Sex (female)

4 (100%)

17 (68%)

8 (40%)

30 (60%)

27 (69.2%)

Age

60.5 (40.5–64)

35 (26–47.5)

33.5 (27–43)

35.5 (27–51.8)

37 (27–47)

Atopy

3 (75%)

21 (80.8%)

20 (100%)

44 (88%)

16 (41%)c

ACQ7

0.86 (0.25–1.89)

0.57 (0.29–1.00)

1.14 (0.86–1.86)a

0.86 (0.43–1.57)

–

FEV1% predicted

92.70 (84.45–100.9)

94.30 (85.25–100.4)

87.25 (79.08–93.90)a

91.6 (83.5–98.5)

96.6 (90.5–105.5)c

FEV1/ FVC

0.72 (0.68–0.79)

0.79 (0.69–0.84)

0.69 (0.64–0.82)a

0.71 (0.65, 0.75)

0.83 (0.77–0.86)c

BDR

3.32 (−0.92–13.88)

4 (0–6.00)

13.97 (5.99–19.33)a

5.9 (2.06–13.75)

3.0 (1.0–5.0)c

FENO (ppb)

28.35 (18.43–86.5)

26.65 (18.63–48.5)

139.5 (95–195.6)ab

49.5 (22.4–134.5)

33 (27.3–38.5)c

ICS use (%)

4 (100%)

18 (72%)

16 (80%)

38 (76%)

–

TCC/ml

6.07 (0.8–6.12)

1.29 (0.73–2.39)

1.88 (1.2–2.84)

1.40 (0.92–2.84)

1.42 (0.90–2.05)

Viability %(non-squamous cells)

80.74 (69.44–88.24)

65.15 (58.39–74.33)

68.57 (57–81.3)

69.38 (59.5–76)

74.45 (57.5–83)

Sputum eosinophils %

0.12 (0–1.04)

0.47 (0–1.33)

5.8 (3.52–11.78)ab

1.358 (0.24–4.61)

0 (0–0.25)c

Total sputum eosinophils × 104 ml

1.48 (0–7.89)

0.65 (0–1.48)

12.31 (4.88–29.20)a

1.53 (0.37–8.81)

0 (0–0.32)c

Sputum neutrophils %

63.14 (61.46–67.47)a

24.24 (13.02–33.14)

26.90 (17.43–40.19)b

27 (17.21–42.82)

32.1 (19.27–45.43)

Total sputum neutrophils ×104 ml

390.5 (49.03–419.4)

31.27 (11.18–55.04)

48.75 (20.79–96.24)

33.94 (15.7–81.6)

47.51 (10.90–73.10)

Sputum macrophages %

32.37 (30.46–35.59)a

68.88 (56.07–77.08)b

62.25 (48.93–67.97)

63.95 (49.76–74.58)

60.49 (45.55–78.44)

Total sputum macrophages × 104 ml

185.2 (28.98–188.5)

90.14 (46.87–146.2)

109.7 (67.18–158.7)

96.80 (53.16–160.6)

80.94 (41.71–125.9)

Sputum lymphocytes%

2.36 (1.16–3.99)

1.47 (0.83–2.32)

2.61 (1.69–4.37)a

1.94 (0.98–3.14)

2.12 (1.25–3.45)

Total sputum lymphocytes × 104 ml

5.93 (1.39–18.09)

1.83 (0.72–2.92)

4.70 (2.24–8.96)a

2.37 (1.15–6.24)

3.15 (1.28–6.22)

Sputum IL-8 (ng/ml)

2.33 (1.47–3.39)

1.77 (1.01–3.08)

2.36 (1.52–3.39)

2.19 (1.26–3.18)

1.62 (1.66–2.33)

Sputum MMP-9

1595 (1084–2943)

528.9 (185.8–1040)

1063 (374–2126)

693.7 (374–1363)

736.7(334.5–1340)

  1. The first three columns report the characteristics of the asthma phenotypes previously described.[5] No MGA phenotype was detected. NA and PGA combined make up the NEA phenotype described in Results [2]
  2. BDR change in FEV1% predicted post bronchodilator. Median (IQR) or number (%)
  3. Comparing EA, NA and PGA:
  4. aSignificantly different (p < 0.05) than PGA
  5. bSignificantly different (p < 0.05) than NA
  6. Comparing asthma and no asthma:
  7. cSignificantly different (p < 0.05) than asthma
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us